Polycystic Ovary Syndrome (PCOS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033


 

Polycystic Ovary Syndrome (PCOS) is a prevalent metabolic disorder characterized by hormonal imbalances in women of reproductive age (between 12 and 51 years). It is associated with elevated levels of male hormones, leading to irregular menstrual cycles, ovulation difficulties, and potential challenges with conception. Additionally, PCOS can manifest as abnormal hair growth on the body and face and may have long-term implications, such as an increased risk of heart disease and diabetes. The etiology of PCOS remains incompletely understood; nevertheless, several significant factors have been identified, including:

  1. Excessive Insulin Production: Elevated insulin levels may stimulate the production of androgens, normally present in lower quantities in females, resulting in ovulation problems.
  2. Excessive Androgen Production: The ovaries produce abnormally high levels of androgen hormones, leading to acne and hirsutism (excessive hair growth on the face and body).
  3. Low-Grade Inflammation: Recent studies indicate that females with PCOS experience low-grade inflammation, contributing to increased androgen production and potential cardiovascular issues.
  4. Heredity: There is evidence of a genetic correlation among women affected by PCOS.

Common signs and symptoms of PCOS in females include irregular menstruation (oligomenorrhea), skipped or absent menstruation (amenorrhea), heavy menstrual bleeding (menorrhagia), excessive hair growth on various body areas, acne, weight gain, hair loss, and skin darkening in specific regions. Only a few agents have received approval from the U.S. Food and Drug Administration specifically for treating polycystic ovary syndrome. Several agents are contraindicated during pregnancy. Insulin-sensitizing agents are recommended for most women with PCOS as they positively affect insulin resistance, menstrual irregularities, anovulation, hirsutism, and obesity. Among these agents, metformin has the most extensive data supporting its effectiveness. Additionally, rosiglitazone and pioglitazone have effectively reduced hirsutism and insulin resistance. Metformin and clomiphene, combined, are considered first-line treatments for inducing ovulation. Furthermore, insulin-sensitizing agents, oral contraceptives, spironolactone, and topical eflornithine may be utilized to manage hirsutism in affected patients.

Thelansis’s “Polycystic Ovary Syndrome (PCOS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Polycystic Ovary Syndrome (PCOS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Polycystic Ovary Syndrome (PCOS) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Polycystic Ovary Syndrome (PCOS) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Polycystic Ovary Syndrome (PCOS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Comments

Post a Comment

Popular posts from this blog

Motor Neurone Disease (MND) – Market Access and Reimbursement Insights Report – 2025

Motor Neurone Disease (MND) Market Access and Reimbursement Insights Thelansis’s “Motor Neurone Disease (MND) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Motor Neurone Disease (MND) Overview Motor neurone disease is a progressive neurological condition in which the nerve cells that control voluntary muscle movement gradually deteriorate. As these neurons are lost, muscles weaken and shrink, leading to increasing difficulty with walking, speaking, swallowing, and eventually breathing. The disease usually begins subtly but advances relentlessly, with most patients facing a shortened life expectancy of only a few ye...
Read more

Retinitis Pigmentosa (RP) – Market Access and Reimbursement Insights Report – 2025

Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Thelansis’s “Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Key business questions answered: Market access and reimbursement for current therapies Coverage on plans Market access restrictions Rebates and contracting Factors influencing formulary access HEOR requirements and influence, etc. Expected market access and reimbursement for key emerging therapies Level of awareness Anticipated coverage on plans Factors that would improve mar...
Read more

Uncomplicated Gonorrhea – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2024 To 2034

  Uncomplicated Gonorrhea Market Outlook Thelansis’s “Uncomplicated Gonorrhea Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Uncomplicated Gonorrhea treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Uncomplicated Gonorrhea Overview Uncomplicated gonorrhea is a common sexually transmitted infection (STI) caused by Neisseria gonorrhoeae, a bacterium that primarily affects the mucous membranes of the genital, rectal, and throat areas. The infection spreads through unprotected sexual contact and often presents mild or no symptoms, making early detection challenging. When symptoms do appear, they generally include a burning sensation...
Read more